The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer

Park, J.H.; McMillan, Donald C.; Horgan, Paul G.; Roxburgh, Campbell S.D.

doi:10.1016/j.ctrv.2013.05.006

Cited by 70 publications

(44 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, in patients with stage III disease, those with mGPS=0 may benefit from adjuvant chemotherapy alone, whereas those with an elevated mGPS may also benefit from the addition of an anti-inflammatory agent, such as aspirin or other NSAID. 24,25 Certainly, it is clear that randomised controlled trials, incorporating both routine assessment of the systemic inflammatory response and use of anti-inflammatory agents, are required.…”

Section: Discussionmentioning

confidence: 99%

Colorectal Cancer, Systemic Inflammation, and Outcome

et al. 2016

View full text Add to dashboard Cite

Running head: colorectal cancer and systemic inflammation 1 Mini-AbstractOf measures of the systemic inflammatory response, the modified Glasgow Prognostic Score has been most extensively validated in cancer. The present study examined its clinical utility in a large cohort of patients undergoing potentially curative resection of colorectal cancer. 2 Abstract ObjectiveThe present study aims to examine the clinical utility of the combination of TNM stage and modified Glasgow Prognostic Score (mGPS) in patients undergoing potentially curative resection of colorectal cancer (CRC). Background

show abstract

Section: Discussionmentioning

confidence: 99%

Colorectal Cancer, Systemic Inflammation, and Outcome

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Much of the evidence describing the role of COX-2 in carcinogenesis derives from observing the actions of COX-2 inhibitors. The direct tumoral effects of COX-2 inhibitors may be related to the inhibition of COX-mediated synthesis of PGE2, which has been shown to increase tumour cell proliferation, decrease apoptosis, increase angiogenesis and increase chemo-and radio-resistance (Park et al, 2014). The interactions between tumour and host cells are mediated by growth factors and cytokines, which act as paracrine factors for endothelial and stromal cells (Tanaka et al, 2012).…”

Section: Cyclo-oxygenasementioning

confidence: 99%

The role of dietary polyphenols in the moderation of the inflammatory response in early stage colorectal cancer

Little

Combet

McMillan

et al. 2015

Critical Reviews in Food Science and Nutrition

View full text Add to dashboard Cite

Current focus in colorectal cancer management is on reducing overall colorectal cancer mortality by increasing the number of early stage cancers diagnosed and treated with curative intent. There is good evidence that screening for colorectal cancer increases the number of early-stage cancers diagnosed and leads to a reduction of cancer specific mortality. Despite the success of the colorectal cancer screening programme in down-staging colorectal cancer, interval cancer rates are substantial and other strategies to reduce colorectal cancer risk and disease recurrence after surgery with curative intent are desirable.

show abstract

“…31,32 The aim of our study was retrospectively to assess a possible correlation between chronic statin use in the adjuvant setting and disease-free survival (DFS) in patients with stage I-III breast cancer.…”

mentioning

confidence: 99%

Statins and risk of breast cancer recurrence.

Sakellakis

Kostaki

Akinosoglou

et al. 2016

JCO

View full text Add to dashboard Cite

Background:The primary end point of our study was to test whether the concurrent use of a statin is related to a lower risk of recurrence and increased relapse-free survival in patients with early breast cancer. Materials and methods:We reviewed 610 female patients with stage I, II, or III breast cancer who had been surgically treated and who had subsequently received at least adjuvant chemotherapy in order to prevent recurrence. Results: Among the 610 patients with breast cancer, 83 (13.6%) were receiving a statin on a chronic basis for other medical purposes. Overall, statin users displayed longer mean relapsefree survival (16.6 vs 10.2 years, P=0.028). After data had been adjusted for patient and disease characteristics, statin users maintained a lower risk of recurrence. This favorable outcome in statin users was particularly evident when we included only younger patients in the analysis (20 vs 10 years, P=0.006). Conclusion: Statins may be linked to a favorable outcome in early breast cancer patients, especially in younger age-groups.

show abstract

The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer

Cited by 70 publications

References 115 publications

Colorectal Cancer, Systemic Inflammation, and Outcome

Colorectal Cancer, Systemic Inflammation, and Outcome

The role of dietary polyphenols in the moderation of the inflammatory response in early stage colorectal cancer

Statins and risk of breast cancer recurrence.

Contact Info

Product

Resources

About